Market Overview

UPDATE: Stifel Nicolaus Initiates Johnson & Johnson at Hold; Fairly Valued

Share:
Related JNJ
3 Most Likely Suitors For Colgate-Palmolive, In Jefferies' View
Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year
Buffett Stocks in Focus: Southwest Airlines (GuruFocus)

Stifel Nicolaus initiated coverage on Johnson & Johnson (NYSE: JNJ) with a Hold rating.

Stifel Nicolaus noted, "We are initiating coverage of Johnson & Johnson (JNJ) with a Hold rating. We see JNJ as a core health care holding and total return vehicle in any environment for investors looking for safety and stability, particularly in these uncertain times. As JNJ continues to resolve recent issues and ex-FX sales growth reaccelerates modestly in each year over the next few years, JNJ shares should sustain its 12.6x forward P/E multiple, in line with the S&P 500."

Johnson & Johnson closed at $69.19 on Monday.

Latest Ratings for JNJ

DateFirmActionFromTo
May 2017JP MorganUpgradesNeutralOverweight
Jan 2017Wells FargoDowngradesOutperformMarket Perform
Nov 2016BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!